Effect of weight reduction on cardiovascular risk factors and cd34-positive cells in circulation

International Journal of Medical Sciences

Volumn 8, Issue 6, 2011, Pages 445-452

  Mikirova, Nina A ^a   Casciari, Joseph J ^a   Hunninghake, Ronald E ^a   Beezley, Margaret M ^a  

^a Riordan Clinic   (United States)

Author keywords

Body composition; Cardiovascular risk factors; Lipid profile; Progenitor cells; Weight reduction

Indexed keywords

CD34 ANTIGEN; CHORIONIC GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PROBIOTIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BASAL METABOLIC RATE; BLOOD CHEMISTRY; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WATER; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIRCULATION; DIET RESTRICTION; DIET SUPPLEMENTATION; DYSLIPIDEMIA; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; LOW CALORY DIET; MALE; OBESITY; RISK FACTOR; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

EID: 80052063634     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.445     Document Type: Article

References (46)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States. 1999-2004. JAMA. 2006; 295: 1549-1555.
2. Schelbert KB. Comorbidities of obesity. Prim Care. 2009; 36: 271-285.
3. Balistreri CR, Caruso C, Candore G. The Role of Adipose Tissue and Adipokines in Obesity-Related Inflammatory Diseases. Mediators Inflamm. 2010;:802078.
4. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009; 54:1847-1856.
5. Yusuf S, Hawken S, Ounpuu S. Obesity and the risk of myo-cardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005; 366: 1640-1649.
6. Wolk R, Berger P, Lennon RJ, Brilakis ES, Somers VK. Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation. 2003; 108: 2206-2211.
7. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Bal-lard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006; 355: 763-778.
8. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999; 341: 1097-1105.
9. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA. 1999; 282: 1530-1538.
10. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation. 2002; 105: 2923-2928.
11. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002; 105: 2696-2698.
12. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96: 939-949.
13. Takahashi T, Kalka C, Masuda H. Ischemia- and cytokine induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5: 434-8.
14. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phe-notype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008; 28: 1584-1595.
15. Schroeter MR, Leifheit M, Sudholt P. Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrinmediated adhesion. Circ Res. 2008; 103: 536-544.
16. Werner N, Junk S, Laufs U. Intravenous transfusion of endo-thelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003; 93: e17-e24.
17. MacEneaney OJ, Kushner EJ, Van Guilder GP, Greiner JJ, Brian L Stauffer BL, DeSouza CA. Endothelial progenitor cell number and colony forming capacity in overweight and obese adults. Int J Obes (Lond). 2009; 33: 219-225.
18. Muller-Ehmsen J, Braun D, Schneider T, Roman Pfister R, Worm N, Wielckens K, Scheid C, Frommolt P, Flesch M. Decreased number of circulating progenitor cells in obesity: beneficial effects of weight reduction. European Heart Journal. 2008; 29: 1560-1568.
19. Van Guilder GP, Hoetzer GL, Dengel DR, Stauffer BL, DeSouza CA. Impaired endothelium-dependent vasodilation in normo-tensive and normoglycemic obese adult humans. J Cardiovasc Pharmacol. 2006; 47: 310-313.
20. Van Guilder GP, Hoetzer GL, Smith DT, Irmiger HM, Greiner JJ, Stauffer BL, DeSouza CA. Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise. Am J Physiol Endocrinol Metab. 2005; 289: E807-E813.
21. Dzau VJ, Gnecchi M, Pachori AS, Morello F, Melo LG. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension. 2005; 46: 7-18.
22. Heida N-M, Müller JP, Cheng IF, Leifheit-Nestler M, Faustin V, Riggert J, Hasenfuss G, Konstantinides S, Schäfer K. Effects of Obesity and Weight Loss on the Functional Properties of Early Outgrowth Endothelial Progenitor Cells. Journal of the American College of Cardiology. 2010; 55: 357-367.
23. Simeons ATW. The action of chorionic gonadotropin in the obese. Lancet 1954;:946-947.
24. Simeons ATW. Chorionic gonadotropin in the obese. Lancet 1962;: 47-48.
25. Rabe T, Richter S, Kiesel L, Runnebaum B. Risk-benefit analysis of a hCG-500 kcal reducing diet (cura romana) in females. Geburtshilfe Frauenheilkd. 1987; 47: 297-307.
26. Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. Br J Clin Pharmacol. 1995; 40: 237-243.
27. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by Flow cytometry. Journal of hematotherapy. 1996; 5: 213-226.
28. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T. Isolation of putative progenitor endothelial cells for angio-genesis. Science. 1997; 275: 964-967.
29. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, Gillebert TC, Plum J, Van-dekerckhove B. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arteri-oscler Thromb Vasc Biol. 2007;27:1572-1579
30. Reaven, G. M. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993; 44: 121-131.
31. Steinberg, H. O, Chaker, H, Leaming, R, Johnson, A, Brechtel, G, Baron, A. Obesity/insulin resistance is associated with en-dothelial dysfunction. J Clin Invest. 1996; 97: 2601-2610.
32. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O, Lechi A. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord. 1999; 23: 936-942.
33. Caballero EA. Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease. Obesity Research. 2003; 11: 1278-1289.
34. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan M. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000; 8: 605-619.
35. Lundman P, Eriksson MJ, Silveira A, Hansson LO, Pernow J, Ericsson CG, Hamsten A, Tornvall P. Relation of hypertriglyc-eridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin -6, soluble adhesion molecules, von Willebrand factor, and endothelin -1). Am J Cardiol. 2003; 91: 1128-1131.
36. Ferreira AC, Peter AA, Mendez AJ, Jimenez JJ, Mauro LM, Chirinos JA, Ghany R, Virani S, Garcia S, Horstman LL, Purow J, Jy W, Ahn YS, de Marchena E. Postprandial Hypertriglycer-idemia Increases Circulating Levels of Endothelial Cell Micro-particles. Circulation. 2004; 110: 3599-3603.
37. Libby P. Vascular biology of athrosclerosis: overview and state of art. Am J Cardiol. 2003; 91: 3A-6A.
38. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995; 57: 791-804.
39. Shmilovich H, Deutsch V, Roth A, Miller H, Keren G, Georg J. Circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart. 2007; 93: 1071-1076.
40. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes. N Engl J Med. 2005; 353: 999-1007.
41. Fadini GP, de Kreutzenberg SV, Coracina A, Baesso I, Agostini C, Tiengo A, Avogaro A. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J. 2006; 27: 2247-2255.
42. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New England Journal of Medicine. 2003; 348: 593-600.
43. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001; 89: E1-E7.
44. Young RL, Fuchs RJ, Woltjen MJ. Chorionic gonadotropin in weight control. A double-blind crossover study. JAMA. 1976; 236:2495-2497.
45. Greenway FL, Bray GA. Human chorionic gonadotropin (HCG) in the treatment of obesity: a critical assessment of the Simeons method. West J Med. 1977; 127: 461-463.
46. Asher WL, Harper HW. Effect of human chorionic gonadotro-phin on weight loss, hunger and feeling of well-being. Am J Clin Nutr. 1973; 26: 211-218.